Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Non Regulatory January 11, 2023Vivesto announces Inceptua decision to withdraw market authorization application for Apealea® in Switzerland
-
Regulatory December 28, 2022Vivesto announces Erik Kinnman to take up CEO position in January
-
Regulatory November 30, 2022Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period
Vivesto published its Q3 report for 2022 on November 17, 2022, at 08.00 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program